about
From unwitnessed fatality to witnessed rescue: Pharmacologic intervention in sudden unexpected death in epilepsyMolecular mechanisms of epilepsyPhysiological bases of the K+ and the glutamate/GABA hypotheses of epilepsy.Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy?Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediatorsCell type-specific effects of adenosine on cortical neurons.Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis?Contribution of extrasynaptic N-methyl-D-aspartate and adenosine A1 receptors in the generation of dendritic glutamate-mediated plateau potentials.Caffeine prevents acute mortality after TBI in rats without increased morbidity.Zebrafish Embryo as an In Vivo Model for Behavioral and Pharmacological Characterization of Methylxanthine Drugs.Safety considerations for patients with epilepsy taking antiepileptic drugs alongside caffeine or other methylxanthine derivatives.Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?Caffeine toxicity in forensic practice: possible effects and under-appreciated sources.Effects of caffeine on cortical epileptic afterdischarges in adult rats are modulated by postnatal treatment.The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude.Xanthine scaffold: scope and potential in drug development
P2860
Q26770025-A80DE1FA-68D1-4AD1-AD35-67AB60826FACQ28087505-92D96689-E699-4B3B-A974-A32AAAB95D91Q30819017-1C3CBC20-5C5B-483E-B755-84E6ED4888D8Q34214636-3C39452F-B405-4B68-B22E-883A08E7C798Q34279284-F3C434EF-35F3-4A91-BC5D-24018F2C22B9Q35053833-0F065CBC-73C3-41BD-9749-0843B9B352D7Q35072901-62817D71-E4FF-431A-BC4A-D9D399795EA9Q35552360-8461CF27-C433-4083-A2EB-9FAAB2488198Q35683627-AFBB7378-5243-4FD4-AEF9-56F2C6F8DBA0Q35803244-72A65FB8-7C36-4AEF-B1D2-951A93C797D0Q37729231-AF169E42-565E-430D-86D6-90B2D1B11179Q38213495-B9341817-0094-4462-814A-60C84FD86028Q38317211-0F6F4FC0-C301-47C0-AB9F-D2E8B561B6AAQ38877023-4F3EA8B7-7325-4FC3-A8BE-96AAEE505D0FQ46147473-A4536210-FFC4-40FA-93F2-C9D84FEF438FQ51317571-2827D24A-3E5A-4C7B-BAB1-B6C638553581Q57298107-839F73EF-33E7-4914-958F-A89C975AB082
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Methylxanthines, seizures, and excitotoxicity.
@ast
Methylxanthines, seizures, and excitotoxicity.
@en
Methylxanthines, seizures, and excitotoxicity.
@nl
type
label
Methylxanthines, seizures, and excitotoxicity.
@ast
Methylxanthines, seizures, and excitotoxicity.
@en
Methylxanthines, seizures, and excitotoxicity.
@nl
prefLabel
Methylxanthines, seizures, and excitotoxicity.
@ast
Methylxanthines, seizures, and excitotoxicity.
@en
Methylxanthines, seizures, and excitotoxicity.
@nl
P2860
P1476
Methylxanthines, seizures, and excitotoxicity
@en
P2093
Detlev Boison
P2860
P304
P356
10.1007/978-3-642-13443-2_9
P577
2011-01-01T00:00:00Z